Back

Residual risk post acute coronary syndroms after 1 year of cardiac rehabilitation. Can we improve it?

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Prognostic parameters after an acute cardiovascular event Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Raul Gascuena

University Hospital Severo Ochoa, Leganes (Spain)

7 More presentations in this session

Presentation thumbnail
How vaccination affects clinical outcomes of COVID-19 positive revascularized patients?
Doctor S. Shahbazova (Baku, AZ)
Abstract Slides
Presentation thumbnail
Defibrillator shocks and their effect on objective asian patient outcomes: results of the painfree SST clinical trial
Associate Professor Y. Kondo (Chiba, JP)
Abstract Slides
Presentation thumbnail
Lipid-lowering prescription patterns after a non-fatal acute coronary syndrome
Professor C. Gavina (Porto, PT)
Abstract Slides
Presentation thumbnail
Trends in risk factor prevalence in young adults experiencing acute coronary syndrome
Mr O. Segal (Haifa, IL)
Abstract Slides
Presentation thumbnail
Is genetic information helpful in predicting recurrent events in young patients after acute coronary syndrome?
Doctor F. Sousa (Funchal, PT)
Abstract Slides

Access the full session

Session thumbnail
Prognostic parameters after an acute cardiovascular event

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Key takeaways: addressing residual cardiovascular risk with proven therapies
thumbnail
Congress Presentation
Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry
thumbnail
Congress Presentation
Efficacy of PCSK9 inhibitors combined with statins versus statin monotherapy for secondary cardiovascular prevention: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources